"studyVersion","studyAcronym","uuid:ID","studyRationale","id","studyTitle"
"2","H2Q-MC-LZZT","66c3a42d-399b-440e-abfb-86c0cfcf88c2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease"
